Results 121 to 130 of about 82,604 (202)

BRAF Inhibitors and Control of Mutant BRAF Effects

Cancer Therapy & Oncology International Journal, 2023
openaire   +1 more source

AI-driven <i>de novo</i> design of BRAF inhibitors with enhanced binding affinity and optimized drug-likeness. [PDF]

PeerJ
Lu Z, Zhang A.
europepmc   +1 more source

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. [PDF]

Int J Mol Sci, 2022
Ragusa F, Ferrari SM, Elia G, Paparo SR, Balestri E, Botrini C, Patrizio A, Mazzi V, Guglielmi G, Foddis R, Spinelli C, Ulisse S, Antonelli A, Fallahi P.   +13 more
europepmc   +1 more source

Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer. [PDF]

Br J Cancer
Rubio-Cuesta B, Carretero-Puche C, Llamas P, Sarmentero J, Gil-Calderon B, Lens-Pardo A, Antón-Pascual B, Rubio-González E, Cámara-Jurado M, Salamanca J, Rueda-Fernández D, Delcuratolo MD, Soldevilla B, Garcia-Carbonero R.   +13 more
europepmc   +1 more source

Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors. [PDF]

Elife
Clayton J, Romany A, Matenoglou E, Gavathiotis E, Poulikakos PI, Shen J.   +5 more
europepmc   +1 more source

p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells. [PDF]

J Biol Chem, 2022
Pietrobono S, De Paolo R, Mangiameli D, Marranci A, Battisti I, Franchin C, Arrigoni G, Melisi D, Poliseno L, Stecca B.   +9 more
europepmc   +1 more source

Novel chalcone 2-thiopyrimidine conjugates as dual VEGFR-2/BRAF inhibitors: design, synthesis, <i>in vitro</i> cytotoxicity, and molecular docking study. [PDF]

RSC Med Chem
Abdelaziz RAI, Allam HA, El Kerdawy AM, Abo-Elfadl MT, Abbas SE, Ghannam IAY.   +5 more
europepmc   +1 more source

BRAF Inhibitor ARQ 736 [PDF]

, 2020
openaire   +1 more source

Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany. [PDF]

Cancer Rep (Hoboken)
Rischke N, Kanbach J, Haug U.
europepmc   +1 more source

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. [PDF]

Neuro Oncol, 2022
Andrews LJ, Thornton ZA, Saincher SS, Yao IY, Dawson S, McGuinness LA, Jones HE, Jefferies S, Short SC, Cheng HY, McAleenan A, Higgins JPT, Kurian KM.   +12 more
europepmc   +1 more source